Ellen Riehle

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study

OBJECTIVE To examine, among patients with type 2 diabetes, the association between hospitalization for heart failure (hHF) and treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is) versus sulfonylureas (SUs), and treatment with saxagliptin versus sitagliptin. RESEARCH DESIGN AND METHODS This was a retrospective, observational study using a U.S. insurance claims database. Patients initiated treatment between 1 August 2010 and 30 August 2013, and had no use of the comparator treatments in the prior 12 months (baseline). Each comparison consisted of patients matched 1:1 on a propensity score. Time to each outcome was compared between matched groups using Cox models. Analyses were stratified by the presence of baseline cardiovascular disease (CVD). Secondary analyses examined associations between comparator treatments and other selected cardiovascular events. RESULTS After matching, the study included 218,556 patients in comparisons of DPP-4i and SU, and 112,888 in comparisons of saxagliptin and sitagliptin. The hazard ratios (HRs) of hHF were as follows: DPP-4i versus SU (reference): HR 0.95 (95% CI 0.78–1.15), P = 0.580 for patients with baseline CVD; HR 0.59 (95% CI 0.38–0.89), P = 0.013 for patients without baseline CVD; saxagliptin versus sitagliptin (reference): HR 0.95 (95% CI 0.70–1.28), P = 0.712 for patients with baseline CVD; HR 0.99 (95% CI 0.56–1.75), P = 0.972 for patients without baseline CVD. Comparisons of the individual secondary and composite cardiovascular outcomes followed a similar pattern. CONCLUSIONS In patients with type 2 diabetes, there was no association between hHF, or other selected cardiovascular outcomes, and treatment with a DPP-4i relative to SU or treatment with saxagliptin relative to sitagliptin.

Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy

Micro‐Abstract Cost considerations could factor into the choice of metastatic colorectal cancer (mCRC) treatment. The present real‐world observational study of 2352 mCRC patients in the United States found that the per‐patient monthly health care costs for first‐line (1L) or 1L through second‐line therapy were substantially greater for patients treated with 1L cetuximab‐containing versus bevacizumab‐containing regimens. Such cost implications could be meaningful in real‐world clinical practice. Background The present study examined real‐world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first‐line (1L) bevacizumab (BEV)‐ or cetuximab (CET)‐containing regimen in 1L or 1L‐through‐second‐line (1L‐2L) therapy. Patients and Methods Using a large US insurance claims database, patients with mCRC initiating 1L BEV‐ or 1L CET‐containing regimen from January 1, 2008 to September 30, 2014 were identified. The per‐patient per‐month (PPPM) all‐cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic‐containing regimen, 1L‐2L therapy. Multivariable regression analyses were used to compare PPPM total health care costs between patients initiating a 1L BEV‐ versus 1L CET‐containing regimen. Results A total of 6095 patients initiating a 1L BEV‐ and 453 initiating a 1L CET‐containing regimen were evaluated for 1L costs; 2218 patients initiating a 1L BEV‐ and 134 initiating a 1L CET‐containing regimen were evaluated for 1L‐2L costs. In 1L therapy, 1L CET had adjusted PPPM costs that were

Costs and Work Loss Burden of Diagnosed Opioid Abuse Among Employees on Workers Compensation or Short-term Disability

3135 (95% confidence interval [CI],

Age-appropriate compliance and completion of up to five doses of pertussis vaccine in US children

1174‐

Real-world cancer regimen costs for metastatic colorectal cancer patients treated with biologics in first- through second-line.

5040; P < .001) greater on average than 1L BEV. In 1L‐2L therapy, 1L BEV‐2L CET had adjusted PPPM costs that were

Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States

1402 (95% CI,

Disease Severity and Baseline Characteristics of Patients Receiving Mepolizumab or Omalizumab in Employer Claims Database: A real-world experience

1365‐

Variation In Opioid Utilization By Physician Specialty And Payer Using A Linked Claims-Emr Database

1442; P = .010) greater than those for 1L BEV‐2L BEV, and 1L CET‐2L BEV had adjusted PPPM costs that were

Treatment patterns and characteristics of acute promyelocytic leukemia (APL) patients receiving arsenic trioxide (ATO) therapy in a real-world setting.

4279 (95% CI,

Comparison of real-world direct healthcare costs for metastatic colorectal cancer patients treated with cetuximab vs. bevacizumab as first-line therapy.

4167‐